Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.

Cancer Chemother Pharmacol 2017 May 30;79(5):1051-1055. Epub 2017 Mar 30.

Assistance publique des Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, Paris, France.

Purpose: Abiraterone acetate combined with prednisone improves survival in metastatic castration-resistant prostate cancer (mCRPC) patients. This oral anticancer agent may result in drug-drug interactions (DDI). We aimed to evaluate the prevalence of DDI with abiraterone and the possible determinants for the occurrence of these DDI.

Methods: We performed a single centre retrospective review from electronic medical records of mCRPC patients treated with abiraterone from 2011 to 2015. Potential DDI with abiraterone were identified using Micromedex and were categorized by a 4-point scale severity.

Results: Seventy-two out of ninety-five mCRPC pts (median age: 77 years [68-82]) had comorbidities. The median number of drugs used per patient was 7 [5-9]. 66 potential DDI with abiraterone were detected in 49 patients (52%): 39 and 61% were classified as major and moderate DDI, respectively. In the univariate analysis, pain (p < 0.0001), hypo-albuminemia (p = 0.032), and higher ECOG performance status (PS) (p = 0.013) were significantly associated with a higher risk of DDI with abiraterone. Pain (p < 0.0001) and PS (p = 0.018) remained significant in the multivariate analysis.

Conclusions: Polypharmacy is an issue among mCRPC patients. In our study, half of the patients have potential DDI with abiraterone. Patients with pain and poor PS are at higher risk of DDI with abiraterone. A medication review by a pharmacist is of crucial importance to prevent DDI with abiraterone.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3291-zDOI Listing
May 2017
35 Reads

Publication Analysis

Top Keywords

ddi abiraterone
12
castration-resistant prostate
8
prostate cancer
8
potential ddi
8
mcrpc patients
8
metastatic castration-resistant
8
drug-drug interactions
8
abiraterone
6
ddi
5
scale severityresults
4
2015 potential
4
abiraterone 2011
4
2011 2015
4
abiraterone identified
4
micromedex categorized
4
identified micromedex
4
treated abiraterone
4
4-point scale
4
categorized 4-point
4
electronic medical
4

References

(Supplied by CrossRef)

J Lees et al.
Lancet Oncol 2011

JS Bono De et al.
N Engl J Med 2011

CJ Ryan et al.
N Engl J Med 2013

A Thomas-Schoemann et al.
Crit Rev Oncol Hematol 2014

A Chan et al.
Clin Ther 2009

KN Chi et al.
Cancer Chemother Pharmacol 2013

JN Graff et al.
Drugs Aging 2014

J Monbaliu et al.
Drug Metab Dispos 2016

A Bernard et al.
Clin Pharmacol Drug Dev 2015

M Extermann et al.
J Clin Oncol 2007

B Hovstadius et al.
Clin Geriatr Med 2012

Similar Publications